Global Biopharmaceutical
and Biomedicine Market, By Product Type (Biopharmaceutical, Nanomedicine,
Gene Therapy, Bioinformatics, and Molecular Enzymes & Kits), By Application
(Therapeutics, Diagnostics, and Research and Development) and by Region (North
America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was
valued at US$ 358.4 Bn in 2016 and is projected to exhibit a CAGR of 9.4% over
the forecast period (2017–2025). Frequent launches and approvals of novel
biopharmaceutical products is expected to drive the market growth in the near
future. In 2017, Sanofi S.A. received U.S. Food and Drug Administration (FDA)
approval for Dupixent (dupilumab) injection to treat adults suffering from
moderate to severe eczema (atopic dermatitis). In 2017, F. Hoffmann-La Roche AG
received FDA approval for Hemlibra (emicizumab-kxwh), indicated to prevent and
reduce bleeding incidents among children and adults suffering from haemophilia
A with factor VIII inhibitors. In 2017, Novo Nordisk A/S received the U.S. FDA
approval for REBINYN (Coagulation Factor IX (Recombinant), GlycoPEGylated)
indicated for treatment and control of bleeding episodes, and perioperative
management of bleeding among children and adults. In 2017, Novo Nordisk
received U.S. FDA approval for Fiasp (Insulin aspart injection). Fiasp is a
fast acting mealtime insulin, which is indicated to improve glycemic control
among adults suffering from type 1 and type 2 diabetes. In 2017, Serum
Institute of India launched its Rabishield, a rabies monoclonal antibody,
developed in partnership with the University of Massachusetts Medical School.
In 2017, Mundipharma GmbH launched its Truxima (rituximab), a biosimilar
monoclonal antibody for the treatment of cancer, in the UK, Germany, Italy, the
Netherlands, Belgium, Republic of Ireland, and Luxembourg, following authorization
by the European Medicines Agency (EMA). The launches and approvals of such
novel biopharmaceutical and biomedicine technologies is expected to create a
conducive environment for growth of the global biopharmaceutical and
biomedicine market.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/18
Browse 45 Market Data Tables and
42 Figures spread through 285 Pages and in-depth TOC on Biopharmaceutical and
Biomedicine Market By Product Type (Biopharmaceutical, Nano medicine, Gene
Therapy, Bioinformatics, and Molecular Enzymes & Kits Market) and Region
(North America, Latin America, Europe, Asia Pacific, the Middle East, and
Africa) - Global Forecast to 2025
Strategic collaboration of key
players and research institutes in the market for the development of
biopharmaceutical and biomedicine technologies is also expected to positively
affect the market growth. For instance, in February 2018, AbbVie Inc. and
Voyager Therapeutics, Inc. entered into a strategic partnership for the
development and commercialization of gene therapies for Alzheimer's disease and
other neurodegenerative diseases. In February 2018, Kite Pharma, Inc., a Gilead
Sciences, Inc. company, collaborated with Sangamo Therapeutics Inc. for
developing engineered cell therapies to treat cancer. As per the agreement,
Kite Pharma, Inc. will use Sangamo Therapeutics’ zinc finger nuclease (ZFN)
gene-editing product type for developing next-generation ex vivo cell therapies
for treatment of cancer. In 2017, The National Institutes of Health collaborated
with 11 leading biopharmaceutical companies to boost the development of new
cancer immunotherapy. The partners include AbbVie Inc., Amgen Inc., Boehringer
Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb, Celgene Corporation,
Genentech Inc., subsidiary of Roche Group, Gilead Sciences, Inc.,
GlaxoSmithKline Plc., Janssen Pharmaceutical Companies of Johnson &
Johnson, Novartis A.G., and Pfizer, Inc. In 2017, AbCellera Biologics, Inc.
collaborated with GlaxoSmithKline plc. for the discovery of monoclonal
antibodies against an undisclosed membrane protein target.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/bio-pharmaceuticals-and-biomedicine-market-18
Key Takeaways of the
Biopharmaceutical and Biomedicine Market:
The global biopharmaceutical and
biomedicine market is expected to exhibit a CAGR of 9.4% over the forecast
period (2017–2025), owing to increasing development of novel technologies and
strategic collaboration of key players in the market for biopharmaceutical and
biomedicine technologies
North America was the dominant
region in the global biopharmaceutical and biomedicine market and is expected
to retain its dominance over the forecast period (2017–2025). This is due to
presence of major key players and increasing funding by various organizations
to support biopharmaceutical researches. For instance, in 2015, National
Institutes of Health (NIH) funded US$ 54 million to support emerging challenges
in biomedical research. NIH has funded to launch four broad scientific Program:
the Glycoscience Program, the 4D Nucleome Program, the Gabriella Miller Kids
First Research Program, and the Science of Behavior Change Program.
Asia Pacific is expected to
exhibit highest growth, with a CAGR of 15.3% over the forecast period, due to
increasing research and development in China in biopharmaceutical and
biomedicine. For instance, in 2016, Chinese scientists injected cells modified
with the CRISPR-Cas9 gene-editing technology in human. This is the first time
in world when researchers from the Sichuan University in Chengdu inserted
re-engineered cells into a lung cancer patient participating in a clinical
trial at the West China Hospital.
Major players operating in the
biopharmaceutical and biomedicine market include Amgen Inc., F. Hoffmann-La
Roche AG, Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli
Lilly and Company, AbbVie Inc., Novo Nordisk A/S, Bristol - Myers Squibb,
NanoString Technologies, Inc., Qiagen N.V., Celgene Corporation, and Affimed
N.V.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/18
About Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent Market
Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment